search
Back to results

A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns (NeuroPAP)

Primary Purpose

Respiratory Failure

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
NeuroBox to deliver the NeuroPAP
Sponsored by
St. Justine's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Failure focused on measuring CPAP, NIV, NIPPV, Edi

Eligibility Criteria

3 Days - 1 Month (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Preterm infants, >26 0/7 and < 34 weeks GA, at least 3 days old and younger than 1 month,
  • on NIPPV with settings in the range : Maximal inspiratory pressure (total, including PEEP) < 20 cmH2O, and PEEP : 5-7 cmH2O,
  • with FiO2 <40%, and stable.

Exclusion Criteria:

  • Suspected or proven pneumothorax
  • Patient on high-flow nasal cannula or nasal continuous positive airway pressure (nCPAP)
  • Infants with severe recurring apnea
  • Recent worsening of respiratory status with increase work of breathing, recent increase in FiO2, or linked with a suspected sepsis
  • Contraindications to the placement of a new nasogastric tube (e.g. severe coagulation disorder, malformation or recent surgery in cervical, nasopharyngeal or esophageal regions)
  • Hemodynamic instability requiring inotropes.
  • Severe respiratory instability requiring imminent intubation according to the attending physician, or FiO2 > 45%, or PaCO2 > 65 mmHg on blood gas in the last hour.
  • Patient for whom a limitation of life support treatments is discussed or decided.
  • Refusal by the treating physician.

Sites / Locations

  • St. Justine's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NeuroBox to deliver the NeuroPAP

Arm Description

Outcomes

Primary Outcome Measures

Time effectively spent with NeuroPAP mode activated during the NeuroPAP period
Percentage
Number of interruption of NeuroPAP during the NeuroPAP period
Number of interruption per patients
Change in respiratory rates between standard NIV andNeuroPAP
% of change
Change in cardiac rates between standard NIV andNeuroPAP
% of change
Change in blood pressure between standard NIV andNeuroPAP
% of change
Change in SpO2 between standard NIV andNeuroPAP
% of change
Change in TcPCO2 between standard NIV andNeuroPAP
% of change

Secondary Outcome Measures

Time spent in asynchrony between standard NIV and NeuroPAP
% of time
Change in trigger delays (ms) between standard NIV andNeuroPAP
Change in non assisted breaths (wasted efforts) between standard NIV andNeuroPAP
% of change
Change in autotriggered breaths between standard NIV and NeuroPAP
Percentage
Change in Mean Airway pressure (cmH2O) between standard NIV and NeuroPAP
Change in End expiratory pressure (PEEP, cmH2O) between standard NIV and NeuroPAP
Change in Mean Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP
Change in Peak Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP
Change in Tonic Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP

Full Information

First Posted
May 26, 2015
Last Updated
January 30, 2017
Sponsor
St. Justine's Hospital
Collaborators
Maquet Cardiovascular
search

1. Study Identification

Unique Protocol Identification Number
NCT02480205
Brief Title
A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns
Acronym
NeuroPAP
Official Title
A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
January 30, 2017 (Actual)
Study Completion Date
January 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
St. Justine's Hospital
Collaborators
Maquet Cardiovascular

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
There is currently a consensus that non-invasive ventilation (NIV) in preterm infants is preferred over intubation. There are two ways of delivering NIV in preterm infants, nasal continuous positive airway pressure (CPAP) or nasal intermittent positive pressure ventilation (NIPPV), where ventilator inflations are delivered intermittently over a fixed end-expiratory pressure. The synchronization in conventional mode is very difficult to obtain in premature infants. In all ventilation modes PEEP (end-expiratory pressure) is fixed. Considering that preterm infants are more likely to develop atelectasis, an active and ongoing management of the PEEP is very important to prevent de-recruitment. A new respiratory support system (NeuroPAP) was developed to address these issues (synchronization problems and control the PEEP). It uses the electrical activity of the diaphragm (EDI) to control the ventilator assist continuously, both during inspiration (principle of NAVA mode) and also during expiration (based on tonic Edi level).
Detailed Description
The mode NeuroPAP will work with the continuous Edi-level and deliver pressures according to the Edi-signal x set NeuroPAP-level, over the whole breath (inspiration and expiration). The NeuroPAP will work between two pressure levels set by the user and named higher Pressure limit (Plimit) and minimum Pressure (Pmin). A safety upper pressure limit (UPL) will also be set. A backup ventilation will be possible. A specific gastric tube equipped with an array of microelectrodes (Edi catheter, Maquet, Solna, Sweden) will be installed after inclusion, by the same oral or nasal route as the tube previously in place. Patients will then be ventilated in the 5 aforementioned conditions: On conventional NIPPV device on clinical settings for a 30 minute period. The investigators will note the mean airway pressure being delivered with the clinical settings and the resulting peak Edi, as well as neural respiratory rate, tonic Edi, Fraction of inspired oxygen (FiO2), and Oxygen saturation by pulse oximetry (SpO2). With NeuroPAP without modification of Pmin (=peep). The exchange of the nasal interface may be necessary, depending on the original interface. FiO2 will initially be the same as previously set in conventional NIPPV. The Pmin will initially be set at the level of PEEP used during conventional NIPPV. A titration maneuver will be conducted to identify the optimal NeuroPAP level. The infant will be ventilated for one hour. Clinical adjustments in pressures and FiO2 are permitted. Safety termination will be established. NeuroPAP with adjusted Pmin: the Pmin in NeuroPAP will be reduced by 2 cm H2O, with the same NeuroPAP level. The patients will be ventilated for one hour. CPAP delivery with NeuroPAP device: the device will be switched to CPAP mode, for a 15 minute period A second 30 minutes period of the conventional NIPPV will be conducted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Failure
Keywords
CPAP, NIV, NIPPV, Edi

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NeuroBox to deliver the NeuroPAP
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
NeuroBox to deliver the NeuroPAP
Intervention Description
The patients will be studied during the following conditions: On conventional NIPPV device with the clinically prescribed settings (30 min) With NeuroPAP and no change of Pmin (=peep) (60 min) With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min) During CPAP delivered with NeuroPAP device (15 min) Again with original NIPPV device and settings for 30 minutes
Primary Outcome Measure Information:
Title
Time effectively spent with NeuroPAP mode activated during the NeuroPAP period
Description
Percentage
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Number of interruption of NeuroPAP during the NeuroPAP period
Description
Number of interruption per patients
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in respiratory rates between standard NIV andNeuroPAP
Description
% of change
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in cardiac rates between standard NIV andNeuroPAP
Description
% of change
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in blood pressure between standard NIV andNeuroPAP
Description
% of change
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in SpO2 between standard NIV andNeuroPAP
Description
% of change
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in TcPCO2 between standard NIV andNeuroPAP
Description
% of change
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Secondary Outcome Measure Information:
Title
Time spent in asynchrony between standard NIV and NeuroPAP
Description
% of time
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in trigger delays (ms) between standard NIV andNeuroPAP
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in non assisted breaths (wasted efforts) between standard NIV andNeuroPAP
Description
% of change
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in autotriggered breaths between standard NIV and NeuroPAP
Description
Percentage
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in Mean Airway pressure (cmH2O) between standard NIV and NeuroPAP
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in End expiratory pressure (PEEP, cmH2O) between standard NIV and NeuroPAP
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in Mean Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in Peak Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV
Title
Change in Tonic Electrical activity of diaphragm (Edi, mcV) between standard NIV and NeuroPAP
Time Frame
up to 30 minutes after reinstitution of the conventional NIPPV

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Days
Maximum Age & Unit of Time
1 Month
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Preterm infants, >26 0/7 and < 34 weeks GA, at least 3 days old and younger than 1 month, on NIPPV with settings in the range : Maximal inspiratory pressure (total, including PEEP) < 20 cmH2O, and PEEP : 5-7 cmH2O, with FiO2 <40%, and stable. Exclusion Criteria: Suspected or proven pneumothorax Patient on high-flow nasal cannula or nasal continuous positive airway pressure (nCPAP) Infants with severe recurring apnea Recent worsening of respiratory status with increase work of breathing, recent increase in FiO2, or linked with a suspected sepsis Contraindications to the placement of a new nasogastric tube (e.g. severe coagulation disorder, malformation or recent surgery in cervical, nasopharyngeal or esophageal regions) Hemodynamic instability requiring inotropes. Severe respiratory instability requiring imminent intubation according to the attending physician, or FiO2 > 45%, or PaCO2 > 65 mmHg on blood gas in the last hour. Patient for whom a limitation of life support treatments is discussed or decided. Refusal by the treating physician.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillaume Emeriaud, MD, PhD
Organizational Affiliation
St. Justine's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gregory Lodygensky, MD, PhD
Organizational Affiliation
St. Justine's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jennifer Beck, PhD
Organizational Affiliation
Li Ka Shing Knowledge Institute. St. Michael's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christer Sinderby, PhD
Organizational Affiliation
Li Ka Shing Knowledge Institute. St. Michael's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Justine's Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1C5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
32269148
Citation
Rochon ME, Lodygensky G, Tabone L, Essouri S, Morneau S, Sinderby C, Beck J, Emeriaud G. Continuous neurally adjusted ventilation: a feasibility study in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2020 Nov;105(6):640-645. doi: 10.1136/archdischild-2019-318660. Epub 2020 Apr 8.
Results Reference
derived

Learn more about this trial

A Pilot Study of Synchronized and Non-invasive Ventilation ("NeuroPAP") in Preterm Newborns

We'll reach out to this number within 24 hrs